NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Hoffmann-La Roche
Numab Therapeutics AG
HiberCell, Inc.
Intensity Therapeutics, Inc.
Atara Biotherapeutics
BeiGene
Federation Francophone de Cancerologie Digestive
Kyowa Kirin Co., Ltd.
Steba Biotech S.A.
MedImmune LLC
Ludwig Institute for Cancer Research
The University of Texas Health Science Center at San Antonio
University of California, San Francisco
Rexahn Pharmaceuticals, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Florida
Eisai Inc.
Generic Devices Consulting, Inc.
Dana-Farber Cancer Institute